Celltrion reported Q2 revenue of 1.3 trillion won and operating profit of 430 billion won, beating the consensus estimate of 400.7 billion won by 7.31%, with YoY growth of 35.21% and 77.32% respectively. Despite the earnings beat, the stock fell 4.19% to 175,900 won, and Korea Investment Securities lowered its target price from 276,418 won to 260,000 won, citing overall weakness in the healthcare sector as investor sentiment shifts toward semiconductor large-caps. Analysts attribute the strong Q2 performance to expanding sales of new biosimilar products, including Remsima SC and Omniclo, which now account for over 60% of the sales mix and have driven gross margin improvements to around 63%.
Celltrion Reports Q2 Revenue of 1.3 Trillion Won
Celltrion recorded Q2 consolidated revenue of 1.3 trillion won and operating profit of 430 billion won. Revenue and operating profit increased 35.21% and 77.32% compared to the same period last year. Operating profit exceeded the consensus estimate of 400.7 billion won compiled before the earnings announcement by 7.31%.
IBK Securities Cites New Biosimilar Products Driving Margin Expansion
Jung Yi-soo, analyst at IBK Investment & Securities, stated that revenue expansion of new biosimilar product lines and improved product mix were the main factors behind the strong results. Jung explained that the sales share of new products such as Remsima SC (infliximab) for autoimmune diseases and Omniclo (omalizumab) for allergic asthma and idiopathic urticaria rose above 60%, likely improving the gross profit margin to around 63%.
Samsung Securities Highlights Seasonal Strength in H2 Outlook
Analysts viewed positively that Celltrion delivered better-than-expected results in the off-season first half. Celltrion's major customer orders are concentrated in the second half. European public tenders are conducted in Q2-Q3 with revenue concentrated in the second half, and hospitals and wholesalers in other countries tend to build inventory at year-end. Seo Geun-hee, analyst at Samsung Securities, stated that since Q2 results exceeded the company's guidance of 400 billion won, there is a high possibility of achieving guidance in the second half as well, entering the seasonal peak period.
Korea Investment Securities Lowers Target Price to 260,000 Won
Despite positive analyst commentary, none of the review reports on Celltrion's Q2 results published raised the target price. Korea Investment Securities lowered its target from 276,418 won to 260,000 won, a reduction of approximately 6%. Analyst Wi Hae-joo of the firm cited the overall weakness of the healthcare sector, setting the target EV/EBITDA multiple at 25x, 17% lower than before. This reflects the phenomenon of the healthcare sector being sidelined by investors due to sentiment concentration toward semiconductor large-caps.
Kiwoom Securities Points to ADC Drug R&D as Re-Rating Catalyst
New drug R&D events were identified as a momentum that could overcome investor sentiment isolation and drive a re-rating of Celltrion's stock price. Heo Hye-min, analyst at Kiwoom Securities, stated that Celltrion's aggressive investment of funds earned from biosimilar sales into R&D to raise valuation could be one of the key strategies to enhance shareholder value. Heo added that as clinical trials of three antibody-drug conjugate (ADC) new drug candidates progress in earnest and R&D results are produced, it will serve as an opportunity for stock price re-rating.
FAQ
What were Celltrion's Q2 revenue and operating profit figures?
Celltrion reported Q2 revenue of 1.3 trillion won and operating profit of 430 billion won, representing YoY increases of 35.21% and 77.32% respectively, and beating the consensus operating profit estimate of 400.7 billion won by 7.31%.
Why did Korea Investment Securities lower Celltrion's target price despite strong Q2 results?
Korea Investment Securities lowered the target price from 276,418 won to 260,000 won, citing overall weakness in the healthcare sector as investor sentiment has shifted toward semiconductor large-cap stocks, leading to the healthcare sector being sidelined by investors.
What does Kiwoom Securities identify as a potential catalyst for Celltrion's stock re-rating?
Kiwoom Securities analyst Heo Hye-min identified new drug R&D events, specifically the progression of clinical trials for three antibody-drug conjugate (ADC) new drug candidates, as a potential catalyst for stock price re-rating as R&D results are produced.
